Description: SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS. Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
Home Page: www.symbiopharma.com
Toranomon 30 Mori Building
Tokyo,
105-0001
Japan
Phone:
81 3 5472 1125
Officers
| Name | Title |
|---|---|
| Mr. Fuminori Yoshida | CEO, President, Corporate Officer & Representative Director |
| Takaaki Fukushima | Executive VP & Corporate Officer |
| Koji Fukushima | Corporate Officer & Chief Medical Officer |
| Yoshiharu Torikai | Corporate Officer |
| Masahiko Okuno | Corporate Officer |
| Hiroyuki Horita | Corporate Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 24.4499 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2665 |
| Price-to-Sales TTM: | 0.024 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 109 |